TrialLeukemia2015

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.

I M Ghobrial et al.PubMed ↗Publisher ↗

No numbers read from the abstract.